Brainsway’s New Deep TMS Depression Study Completion: What Investors Should Watch Next

Brainsway (BWAY) announced an update on their ongoing clinical study.

The study A Prospective, Randomized, Controlled, Multicenter Trial tests a new stimulation protocol for Brainsway’s Deep TMS system in major depressive disorder. It aims to show the new approach works at least as well as the current standard treatment, which could support easier or more attractive use in real-world clinics.

The intervention is Brainsway’s Deep TMS device, a non-drug treatment that uses magnetic pulses to stimulate brain regions tied to mood. The trial compares a new stimulation schedule against Brainsway’s already cleared protocol to see if similar or better benefits can be achieved.

The study is interventional with patients randomly assigned to one of two groups. It uses a parallel design with two arms run in tandem, and both investigators and outcome assessors are masked to limit bias and keep results clean.

The trial’s primary focus is treatment of major depressive disorder, not diagnosis or prevention. The goal is to confirm safety and effectiveness of the new protocol, which could help expand clinical options while staying within established Deep TMS technology.

The study was first submitted on April 5, 2024, marking the formal start of regulatory tracking. The overall study is now listed as completed, and the latest update on March 9, 2026, signals that follow up and data handling have advanced far enough to refresh the public record.

Primary completion and full completion dates will indicate when all main outcomes and longer term follow up are finished. These milestones matter because Brainsway can only move to label updates, marketing claims, or broader rollout after full analysis of the collected data.

For investors in Brainsway (BWAY), a completed trial with a new protocol is a key trigger for future growth. If results show the new regimen matches or beats the current one, it could boost device appeal versus drug treatments and other brain stimulation players.

Competitors in neuromodulation and depression care, such as other TMS device makers and drug companies, are also pushing new options. Positive signals from this trial could lift sentiment toward BWAY as a focused TMS platform play and support a valuation premium versus slower innovators.

At this stage, the lack of posted results means investors must weigh timing risk and regulatory steps before assuming revenue impact. Still, a completed deep TMS trial in major depression adds credibility to Brainsway’s pipeline and may support a stronger narrative in future capital markets events.

The Brainsway study is completed and recently updated, and more detailed information is available on the ClinicalTrials portal under NCT06357832.

To learn more about BWAY’s potential, visit the Brainsway drug pipeline page.